The final project event – VANGUARD Symposium – will take place on Monday, June 30th, 2025, in London, UK, as part of the ESOT Congress 2025. We are thankful to our ESOT partners for making it possible.
Learn more here.
Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies.
There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.
The VANGUARD project aims to generate a vascularized and immune-protected bioartificial pancreas that can be transplanted into non-immuno-suppressed patients by combining advanced tissue engineering strategies.
This approach will yield a cell therapy in the form of an Advanced Therapy Medicinal Product (ATMP), which can significantly improve treatment of type 1 diabetes.
Last week, the VANGUARD consortium gathered for the final time in person before the conclusion of the project in June 2025. The two-day face-to-face meeting took place on 28-29 April
On 25-26 January 2024, the biannual VANGUARD General Assembly took place in Innsbruck-Igls, Austria. Seventeen representatives from the consortium’s eight project partners gathered for a two-day event focused on project
On 14th November 2024, the University of Geneva (UNIGE) hosted Diabetes Days 2024, an event dedicated to raising awareness about diabetes and highlighting advancements in research. Organised by the Faculty
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 874700